CTS2190 Phase I /II Clinical Study in Patients

This early-phase study is testing the safety and dosing of an experimental drug called CTS2190 in people with advanced solid tumors — including pancreatic cancer, non-small cell lung cancer, stomach cancer, and colorectal cancer — that have not responded to standard treatments. **You may be eligible if...** - You are 18 years old or older - You have advanced or metastatic solid tumors that have failed standard treatment options - Your tumor is measurable on imaging - Your overall health status is acceptable (ECOG 1 or below) - Your heart, liver, kidney, and blood function are adequate - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active brain metastases causing symptoms (stable treated brain metastases may be acceptable) - You have had a major cardiovascular event (heart attack, stroke) in the past 6 months - You have active hepatitis B, C, or HIV - You have a serious autoimmune disease - You have had recent major surgery (within 4 weeks) - You have uncontrolled infection, bleeding, or blood clotting disorders Talk to your doctor to see if this trial is right for you.